Navigation Links
Misonix Receives First Award for Forensic Equipment in China
Date:7/21/2009

FARMINGDALE, N.Y., July 21 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced receipt of its first award for forensic equipment in China from the Company's distributor CSI Technology/CStrace International. This equipment will be supplied to Chinese Law Enforcement in a major city in China. This award came from a competitive bid which focused on quality and performance. The Company expects to deliver the order in our second fiscal quarter 2010.

Michael A. McManus, Jr., President and CEO stated, "We are pleased with the first award for our Forensic products in China. The fact that the Chinese are looking for a value proposition that includes both competitive pricing and high quality suggests the manner in which the market assesses our products. We hope to win more bids as we increase our penetration into the Chinese market."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Kevin McGrath
    Cameron Associates, Inc.
    212-245-4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces Participation in 2nd International Workshop on Focal Therapy
2. Misonix Subsidiary, Sonora Medical Systems, Achieves ISO 17025 Accreditation
3. Misonix Announces the Purchase of Patents From ProRhythm, Inc.
4. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
5. Misonix Announces Participation in Annual Diabetic Foot Global Conference
6. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
7. Misonix Announces New HIFU Distribution Agreement For Portugal
8. Misonix Announces New HIFU Distribution Agreement for Romania and Bulgaria
9. Misonix Announces New Distribution Agreement for Portugal
10. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
11. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Axiad IDS , a leading ... Applications magazine has named the company a “Top 25 Cybersecurity Companies 2017.” ... to help organizations simply and proactively address potential cybersecurity threats before they happen. ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... a 2017 Best in KLAS category winner, has named Daniel P. Bullington as ... and enhance its technology platform and product offerings,” says Justin Neece, president. “Daniel ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... are educating patients on peri-implantitis in Las Vegas, NV, and the ... a custom gum disease consultation and leading care for peri-implantitis, with or without ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients with symptoms of ... breath, can now receive laser gum disease treatments from the doctors at Art of ... Landau are raising awareness of the importance of receiving qualified treatment in order to ...
(Date:5/22/2017)... Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics ... be administered for a variety of treatments. One or more sedation methods may be ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... 2017  A new tight-tolerance microextrusion medical tubing ... materials, is being launched by Natvar, a Tekni-Plex ... in recent years to service a wide variety ... More expensive materials such as glass and fluoropolymers ... to their ability to consistently hold tolerances. This ...
(Date:5/3/2017)... , May 3, 2017 A Catheterization ... hospital or healthcare facility. Commonly referred to as ... equipped with diagnostic imaging technology to give physicians ... heart. In these spaces, a team of physicians ... angioplasty, percutaneous coronary intervention, congenital heart defect closure, ...
(Date:5/3/2017)... May 3, 2017  Getinge, a leading global ... quality enhancement and cost efficiency within healthcare and ... of contemporary practice demonstrating that intra-aortic balloon counterpulsation ... critically ill patients. The single-center, retrospective, observational study ... volume MEGA ® 50cc intra-aortic balloon (IAB) ...
Breaking Medicine Technology: